Incorporating the Extracellular Matrix: New Challenges and Opportunities in Cancer Research
12 Sept 2013
At least 80% of cancers are carcinomas, or tumours of the epithelia. Traditionally, cell transformation to a cancerous stage was evaluated by anchorage dependent growth, an assay more suited for fibroblasts. More recently, the role of the extracellular matrix (ECM), already established in normal epithelial biology, has come to the fore in the study of carcinomas. Watch the video to find out more about ECM proteins, substrates, 3D cell culture products and services most relevant to cancer research and drug screening.
About the company
AMSBIO
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries.
The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.
